Abirakast (Abiraterone Acetate) 250 mg
Abirakast is an effective anti-cancer medication used in the management of prostate cancer. Active ingredient: Abiraterone Acetate (250 mg).
Manufacturer: Aprazer Healthcare (India). A generic version of Zytiga. It works as a selective inhibitor of the enzyme CYP17, essential for androgen biosynthesis.
Benefits:
- ✅ Significantly extends survival rates in mCRPC patients.
- ✅ Delays the need for chemotherapy and reduces cancer-related pain.
- ✅ Must be co-administered with prednisone.
Treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men.
Indicated for use in combination with prednisone or prednisolone for:
- Patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
- Patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).
Daily Dose: 1,000 mg (4 tablets of 250 mg) taken once a day.
⚠️ IMPORTANT SAFETY RULE:
- 🚫 Take on an empty stomach. No food should be consumed for at least 2 hours before and 1 hour after the dose.
- Systemic exposure to abiraterone increases significantly when taken with food, increasing the risk of side effects.
- Swallow whole with water.
Co-medication: Take with low-dose prednisone (usually 5 mg twice daily) to manage mineralocorticoid-related side effects.
- Severe hepatic impairment (Child-Pugh Class C).
- Hypersensitivity to the active substance.
- Pregnancy or women who may become pregnant.
Warning: This drug is not for use in women. Pregnant women should not handle the medication without gloves due to potential harm to the fetus.
Common adverse reactions (often managed by prednisone):
- Fluid retention (edema).
- Hypokalemia (low potassium).
- Hypertension.
- Fatigue and joint pain.
Liver function tests (ALT/AST) and bilirubin should be monitored regularly.
Similar products
What Customers Say
No reviews yet
Your review can be the first!